At a glance
- Originator Nonindustrial source
- Developer Meiji Seika Kaisha; Nonindustrial source
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Jun 2001 No-Development-Reported for Cancer in Japan (Unknown route)
- 04 Aug 1998 Profile reviewed
- 04 Aug 1997 Preclinical development for Cancer in Canada (Unknown route)